Evidence map›Paper›PMID 38416868›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2024

o-Vanillin binds covalently to MAL/TIRAP Lys-210 but independently inhibits TLR2.

Md Habibur Rahaman, Sara J Thygesen, Michael J Maxwell, Hyoyoung Kim, Prerna Mudai, Jeffrey D Nanson, Xinying Jia, Parimala R Vajjhala, Andrew Hedger, Irina Vetter and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Md Habibur RahamanSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia.ORCID 0000-0001-6932-1505
Sara J ThygesenSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia.ORCID 0000-0002-7512-4097
Michael J MaxwellCentre for Advanced Imaging, University of Queensland, Brisbane, Australia.
Hyoyoung KimSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia.ORCID 0000-0003-3635-8234
Prerna MudaiSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia.
Jeffrey D NansonSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia.ORCID 0000-0003-1306-1948
Xinying JiaCentre for Advanced Imaging, University of Queensland, Brisbane, Australia.
Parimala R VajjhalaSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia.
Andrew HedgerSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia.ORCID 0000-0002-0713-0057
Irina VetterInstitute for Molecular Bioscience, University of Queensland, Brisbane, Australia.ORCID 0000-0002-3594-9588
Thomas HaselhorstInstitute for Glycomics, Griffith University, Southport, Australia.ORCID 0000-0002-3373-8680
Avril A B RobertsonSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia.ORCID 0000-0002-9652-8357
Brian DymockQueensland Emory Drug Discovery Initiative, University of Queensland, Brisbane, Australia.ORCID 0000-0002-2374-5756
Thomas VeInstitute for Glycomics, Griffith University, Southport, Australia.ORCID 0000-0002-0113-1905
Mehdi MobliCentre for Advanced Imaging, University of Queensland, Brisbane, Australia.ORCID 0000-0003-2420-4262
Katryn J StaceySchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia.ORCID 0000-0002-3992-7802
Bostjan KobeSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia.ORCID 0000-0001-9413-9166
The University of Queensland · AUGriffith University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toll-like receptor (TLR) innate immunity signalling protects against pathogens, but excessive or prolonged signalling contributes to a range of inflammatory conditions. Structural information on the TLR cytoplasmic TIR (Toll/interleukin-1 receptor) domains and the downstream adaptor proteins can help us develop inhibitors targeting this pathway. The small molecule o-vanillin has previously been reported as an inhibitor of TLR2 signalling. To study its mechanism of action, we tested its binding to the TIR domain of the TLR adaptor MAL/TIRAP (MAL

Indexed as

BenzaldehydesLysineToll-Like Receptor 2AnimalsHumansMembrane GlycoproteinsMiceMyeloid Differentiation Factor 88Receptors, Interleukin-1Toll-Like Receptor 4Toll-Like Receptors2-vanillinBenzaldehydesLysineMembrane GlycoproteinsMyeloid Differentiation Factor 88Receptors, Interleukin-1TIRAP protein, humanTIRAP protein, mouseTLR2 protein, humanToll-Like Receptor 2Toll-Like Receptor 4Toll-Like ReceptorsCovalent modificationMyD88 adaptor-like (MAL)nuclear magnetic resonance (NMR)o-vanillinToll/interleukin-1 receptor domain-containing adaptor protein (TIRAP)Toll-like receptor (TLR)

Identifiers

PMID38416868
PMCPMC10903754
OpenAlexW4392230219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.